-
Ajinomoto Bio-Pharma Services Awarded Three ‘CDMO Leadership Awards’
-
Ajinomoto Bio-Pharma Services Successfully Develops Highly Functional Ancestral RNA Ligase
-
Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
-
Notice of Qualified Invoice Issuer Registration Number
GeneDesign, Inc. – Osaka Site
-
Ajinomoto Bio-Pharma Services Awarded Two ‘CMO Leadership Awards’
-
Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance
-
Notice on email address (for business use) changing
-
Notice on email address changing
GeneDesign, Inc. – Osaka Site
-
[Reminder] Notice on email address domain changing
-
Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity with New Multi-Purpose Fill Suite
-
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing
-
Ajinomoto Co., Inc. and Bright Peak Therapeutics Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines